Completed Statistical Analyses of LEVEL Yielded a Predictive Enrichment Strategy Being Applied in Amended LEVEL-2 Protocol
Company Has Been Granted a Type C Meeting with the FDA
On
According to
On
On
“Analysis of the results of the LEVEL trial provides insights into those patients who exhibit a significant improvement in exercise tolerance. With treatment continuing for those randomized prior to October, we believe we have now taken the steps necessary to ensure our LEVEL-2 protocol population will be enriched with these more symptomatic patients,” said
Recent Corporate and Clinical Highlights
- In
August 2026 , Tenax announced topline results from the Phase 3 LEVEL clinical trial of TNX-103 (oral levosimendan) in patients with PH-HFpEF. LEVEL did not meet its primary endpoint of improvement in 6MWD versus placebo. However, in a prespecified analysis, patients with a baseline 6MWD below the trial median of 333 meters showed a 26.3-meter improvement compared to placebo (95% CI 6.0, 46.7; nominal p=0.0112).- In prespecified exploratory analyses in the overall trial population, treatment with TNX-103 resulted in a 49% greater reduction in NT-proBNP compared to placebo (nominal p<0.0001) and a 3.5 mmHg reduction in RVSP compared to placebo (nominal p=0.0045).
- TNX-103 was generally safe and well tolerated, with serious adverse events and adjudicated clinical worsening events balanced across treatment groups.
- In
August 2026 , LEVEL results were presented bySanjiv Shah , MD, Director of the HFpEF Program atNorthwestern University Feinberg School of Medicine and LEVEL’s Principal Investigator, in a Late-Breaking Clinical Science session at theESC Congress 2026 inMunich, Germany .- Approximately 20 echocardiographic parameters improved with TNX-103 compared to placebo, and no significant arrhythmias were observed across the overall trial population.
- With full statistical analysis now complete, the Company confirms TNX-103’s biological effects include marked reductions in PAP and NT-proBNP, a biomarker reflecting increased cardiac wall stress.
- Based on multivariable analyses of LEVEL, Tenax has temporarily paused enrollment and is amending the protocol for LEVEL-2, its ongoing global Phase 3 clinical trial, to enrich for patients with either a baseline 6MWD of 100 to 300 meters, or a baseline 6MWD of 301 to 400 meters and a right atrial volume index (RAVI) of at least 25 mL/m².
- In LEVEL patients meeting these criteria, TNX-103 showed a 34-meter improvement in 6MWD compared to placebo at Week 12 (95% CI 15, 53; nominal p=0.001).
- Enrollment in LEVEL-2 has been temporarily paused while the amendment is implemented.
- Tenax shared the topline LEVEL results with the FDA in mid-August and has been granted a Type C meeting to discuss the overall development of levosimendan in PH-HFpEF.
- Tenax expects to publish the LEVEL-2 protocol design paper and to provide further updates on the development of levosimendan in the first quarter of 2027.
Third Quarter 2026 Financial Results
Cash position:
Research and development (R&D): R&D expenses for the third quarter of 2026 were
Selling, General and administrative (SG&A): SG&A expenses for the third quarter of 2026 were
Net loss:
About Levosimendan (TNX-101, TNX-102, TNX-103)
Levosimendan is a novel, first-in-class K-ATP channel activator/calcium sensitizer currently being evaluated to treat pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (PH-HFpEF). Levosimendan was first developed for intravenous use in hospitalized patients with acutely decompensated heart failure, and it has received market authorization in 60 countries in this indication, although it is not available in
About Tenax Therapeutics
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit www.tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.
Caution Regarding Forward-Looking Statements
Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. These forward-looking statements may include information concerning our clinical trials and our possible or projected future business operations. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: risks of our clinical trials, including, but not limited to, the timing, delays, costs, design, location, initiation, enrollment, and results of such trials, including that the Phase 3 LEVEL trial did not meet its primary endpoint of change in 6-minute walk distance (6MWD) in the overall enrolled population; the risk that, if LEVEL-2 fails or regulators require additional trials, we may be unable to continue development of TNX-103 and may need to pursue strategic alternatives; the risk that subgroup and post hoc analyses of LEVEL may not be confirmed in LEVEL-2 or accepted by regulators, physicians or investors, and that enriching enrollment in LEVEL-2 may slow enrollment, reduce the commercial opportunity for TNX-103 or result in narrower labeling; the pause in LEVEL-2 enrollment and the implementation of the LEVEL-2 protocol amendment; the outcome of our Type C meeting with the FDA, including the risk that the FDA may disagree with our revised development plan or the amended LEVEL-2 design or require additional trials or a larger or longer safety database; any delays in regulatory review and approval of product candidates in development; our estimates regarding the potential market opportunity for our product candidates; reliance on third parties, including Orion Corporation, our manufacturers and CROs; risks regarding the formulation, production, marketing, customer acceptance and clinical utility of our product candidates; the potential advantages of our product candidates; risks related to our business strategy, including the prioritization and development of product candidates; our competitive position; our ability to maintain our culture and recruit, integrate and retain qualified personnel and advisors, including our executives and on our Board of Directors, including following the LEVEL results and the decline in our stock price; risks associated with our cash needs, including the assumptions underlying our expected cash runway, and our ability to raise additional capital on acceptable terms, and the potential for any such financing to be highly dilutive; the outcome of securities litigation, derivative claims, or regulatory inquiries arising from the LEVEL results; intellectual property risks; volatility and uncertainty in the global economy and financial markets in light of unexpected changes in tariffs and the possibility of pandemics, global financial and geopolitical uncertainties, including in the Middle East and the Russian invasion of and war against the country of Ukraine; changes in legal, regulatory and legislative environments in the markets in which we operate, and the impact of these changes on our ability to obtain regulatory approval for our products; and other risks and uncertainties set forth from time to time in our SEC filings, including those described under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. Tenax Therapeutics assumes no obligation and does not intend to update these forward-looking statements except as required by law.
Contact:
Investor and Media:
Argot Partners
tenax@argotpartners.com
2026 | 2025 | ||||||||
| ASSETS | (unaudited) | ||||||||
| Current assets: | |||||||||
| Cash and cash equivalents | $ | 113,729 | $ | 97,565 | |||||
| Prepaid expenses | 3,177 | 5,643 | |||||||
| Other current assets | 108 | 1,019 | |||||||
| Total current assets | 117,014 | 104,227 | |||||||
| Total assets | $ | 117,014 | $ | 104,227 | |||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||
| Current liabilities: | |||||||||
| Accounts payable | $ | 6,570 | $ | 6,041 | |||||
| Accrued liabilities | 1,785 | 1,115 | |||||||
| Total current liabilities | 8,355 | 7,156 | |||||||
| Total liabilities | 8,355 | 7,156 | |||||||
| Stockholders' equity: | |||||||||
| Preferred stock, undesignated, authorized 4,818,654 shares | |||||||||
| Series A Preferred stock, par value | - | - | |||||||
| Common stock, par value | 5 | 1 | |||||||
| Additional paid-in capital | 526,331 | 464,524 | |||||||
| Accumulated deficit | (417,677 | ) | (367,454 | ) | |||||
| Total stockholders’ equity | 108,659 | 97,071 | |||||||
| Total liabilities and stockholders' equity | $ | 117,014 | $ | 104,227 | |||||
| (Amounts in thousands, except share and per share data) | ||||||||||||||||
| For the three months ended | For the nine months ended | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Operating expenses | ||||||||||||||||
| Research and development | $ | 12,068 | $ | 10,328 | $ | 36,457 | $ | 22,132 | ||||||||
| Selling, general and administrative | 5,660 | 6,478 | 16,628 | 17,804 | ||||||||||||
| Total operating expenses | 17,728 | 16,806 | 53,085 | 39,936 | ||||||||||||
| Net operating loss | (17,728 | ) | (16,806 | ) | (53,085 | ) | (39,936 | ) | ||||||||
| Interest income | 1,036 | 1,017 | 2,878 | 2,901 | ||||||||||||
| Other income (expense), net | (12 | ) | (15 | ) | (16 | ) | (24 | ) | ||||||||
| Net loss | $ | (16,704 | ) | $ | (15,804 | ) | $ | (50,223 | ) | $ | (37,059 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.31 | ) | $ | (0.40 | ) | $ | (1.01 | ) | $ | (0.96 | ) | ||||
| Weighted average number of common shares and prefunded warrants outstanding, basic and diluted | 53,452,869 | 39,741,404 | 49,880,130 | 38,644,395 | ||||||||||||
Source: 